Ligand Pharmaceuticals Incorporated logo
Ligand Pharmaceuticals Incorporated LGND
$ 202.41 2.07%

Quarterly report 2025-Q3
added 11-07-2025

report update icon

Ligand Pharmaceuticals Incorporated Financial Statements 2011-2026 | LGND

Annual Financial Statements Ligand Pharmaceuticals Incorporated

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

2.22 B 1.36 B 1.21 B 2.07 B 3 B 1.71 B 2.49 B 3.47 B 2.11 B 1.98 B 1.16 B 1.28 B 397 M 241 M

Shares

18.3 M 17.3 M 16.9 M 16.6 M 16.2 M 19 M 21.2 M 21 M 20.8 M 19.8 M 20.4 M 20.3 M 19.9 M 19.7 M

Historical Prices

121 78.5 72 125 185 87.8 118 158 106 100 56.9 61.9 20.1 12.4

Net Income

-4.03 M 52.2 M -33.4 M 57.1 M -2.98 M 629 M 143 M 12.6 M -1.64 M 257 M 12 M 11.4 M -527 K 10.2 M

Revenue

167 M 131 M 196 M 242 M 164 M 120 M 251 M 141 M 109 M 71.9 M 64.5 M 49 M 31.4 M 30 M

Cost of Revenue

- - - - - - 6.34 M 5.37 M 5.57 M - - - - -

Gross Profit

- - - - - 109 M 245 M 136 M 103 M 66.1 M 55.4 M 43.2 M 27.8 M 25.1 M

Operating Income

-22.6 M 11.9 M 3.04 M 104 M 37.5 M 807 M 164 M 68.1 M 43.9 M 27.3 M 19.6 M 14.9 M 193 K -878 K

Interest Expense

-54.9 M -1.7 M 4.19 M 19.6 M 27.4 M 35.7 M 48.3 M 13.5 M 12.8 M 1.77 M 4.86 M 2.08 M 2.92 M 2.51 M

EBITDA

12.6 M 48.5 M 54.6 M 155 M 63.2 M 11.1 M 180 M 80.2 M 55.6 M 31 M 23.4 M 18.6 M 3.62 M 2.65 M

Operating Expenses

- - - - - 115 M 81.4 M 67.7 M 58.5 M 37.8 M 34.7 M 27.3 M 26.9 M 25.3 M

General and Administrative Expenses

78.7 M 52.8 M 70.1 M 46.8 M 60 M 41.9 M 37.7 M 28.7 M 26.6 M 24.4 M 22.6 M 18 M 16.1 M 15 M

All numbers in USD currency

Quarterly Income Statement Ligand Pharmaceuticals Incorporated

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

19.6 M 19.3 M 19.2 M 19.1 M 18.4 M 18 M 17.7 M 17.6 M 17.4 M 17.3 M 17.1 M 17 M 16.9 M 16.9 M 16.8 M 16.8 M 16.7 M 16.7 M 16.4 M 16.1 M 16.1 M 16.1 M 16.5 M 17.2 M 18.8 M 19.6 M 20.4 M 21.1 M 21.1 M 21.2 M 21.2 M 21.1 M 21.1 M 21.2 M 21.2 M 20.9 M 20.9 M 20.8 M 20.7 M 19.9 M 19.9 M 19.7 M 19.6 M 19.9 M 20.4 M 20.7 M 20.6 M 20.4 M 20.4 M 20.3 M 20.2 M 20 B 19.9 B 19.7 B 19.7 B 19.7 M 19.7 M 19.6 M 19.6 M

Net Income

117 M 4.85 M -42.5 M - -7.17 M -51.9 M 86.1 M - -10.3 M 2.29 M 41.9 M - 404 K -895 K -15.4 M - 13.7 M 30.7 M 18.1 M 5.76 M -6.7 M 22.1 M -24.1 M -7.36 M -15.3 M -14.4 M 666 M -42.5 M 67.4 M 73.2 M 45.3 M -42.5 M 67.4 M 73.2 M 45.3 M -3.12 M 1.05 M -6.17 M 6.61 M 6.34 M 199 M 23.6 M 754 K 7.06 M 1.28 M 1.59 M 2.1 M 1.87 M 1.96 M 6.09 M 1.5 M 1.06 M -194 K -2.53 M 1.13 M 4.69 M -4.18 M -422 K 9.62 M

Revenue

115 M 47.6 M 45.3 M - 51.8 M 41.5 M 31 M - 32.9 M 26.4 M 44 M - 59.2 M 50.1 M 36.5 M - 64.8 M 84.7 M 55.2 M 70 M 41.8 M 41.4 M 33.2 M 27 M 24.8 M 25 M 43.5 M 59.6 M 45.7 M 90 M 56.2 M 50.5 M 33.4 M 28 M 29.3 M 38.2 M 21.6 M 19.5 M 29.6 M 21.2 M 17.7 M 18.4 M 14.6 M 23 M 15 M 10.6 M 16 M 14.7 M 13 M 9.58 M 11.7 M 13.6 M 6.38 M 5.74 M 5.64 M 12.9 M 5.74 M 7.46 M 3.9 M

Cost of Revenue

- - - - - - - - - - - - - - - - - - - - - - - - 3.15 M 2.4 M 3.86 M - 1.46 M 1.13 M 788 K - 2.38 M 903 K - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

54.9 M 8.44 M -36.2 M - 3.14 M -19.1 M 2.99 M - 3.08 M -1.98 M 14.2 M - 12.3 M 8.66 M 2.13 M - 15.7 M 45.7 M 4.72 M - 3.75 M 7.1 M 3.79 M - -5.16 M -4.13 M 827 M - 23.4 M 70.2 M 37 M - 16.5 M 13 M 10.2 M - 5.47 M 3.97 M 15.1 M - 8.6 M 4.36 M 3.35 M - 3.53 M 1.36 M 5.1 M - 3.07 M 1.51 M 3.93 M - -1.42 M -1.82 M -839 K - -3.25 M -810 K -1.48 M

Interest Expense

-443 K 1.37 M -2.5 M - -9.47 M -33.5 M -2.19 M - -4.3 M -873 K 240 K - 332 K 438 K 789 K - 4.44 M 4.88 M 5.83 M - 6.27 M 6.21 M 8.55 M - 8.99 M 9.01 M 8.91 M - 11.2 M 13.5 M 3.48 M - 3.39 M 3.34 M 2.94 M - 3.12 M 3.05 M 3 M - 2.93 M 2.97 M 2.97 M - 1.52 M 181 K 248 K - 394 K 453 K 912 K - 735 K 762 K 701 K - 699 K 674 K 423 K

EBITDA

- - -27.4 M - - - 11.8 M - - - 23.7 M - 52.7 M 35.6 M 15.8 M - 53.6 M 70.9 M 17.3 M - 16.4 M 15 M 7.21 M - 6.49 M 3.57 M 830 M - 34.8 M 76.2 M 40 M - 24.1 M 18.6 M 13.2 M - 13.8 M 9.36 M 17.7 M - 9.24 M 5 M 4 M - 4.19 M 2.03 M 5.77 M - 3.74 M 2.18 M 4.6 M - -787 K -1.14 M -161 K - -2.51 M 539 K -919 K

General and Administrative Expenses

28.4 M 20.2 M 18.8 M - 24.5 M 17.6 M 11 M - 14.7 M 11.3 M 10.9 M - 14.9 M 12.1 M 11.9 M - 12.7 M 14.7 M 12.6 M - 15 M 10.1 M 9.26 M - 9.52 M 11 M 11.1 M - 9.63 M 9.29 M 7.64 M - 7.03 M 6.55 M 7.32 M - 6.55 M 7.24 M 7.07 M - 4.97 M 7.22 M 5.99 M - 6.74 M 5.24 M 5.07 M - 4.76 M 4.31 M 4.5 M - 4.31 M 3.86 M 3.42 M - 3.96 M 3.86 M 3.44 M

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Ligand Pharmaceuticals Incorporated LGND
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Ligand Pharmaceuticals Incorporated plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.74 3.6 % $ 1.12 B canadaCanada
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Agenus Agenus
AGEN
$ 3.36 0.86 % $ 1.2 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
$ 29.16 -3.54 % $ 1.69 B usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
Фармсинтез Фармсинтез
LIFE
- - - russiaRussia
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Alector Alector
ALEC
$ 2.19 -9.77 % $ 226 M usaUSA
Entera Bio Ltd. Entera Bio Ltd.
ENTX
$ 1.38 -0.72 % $ 63.3 M israelIsrael
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Altimmune Altimmune
ALT
$ 4.21 -2.32 % $ 299 M usaUSA
Teligent, Inc. Teligent, Inc.
TLGT
- -13.85 % $ 16.1 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Evogene Ltd. Evogene Ltd.
EVGN
$ 0.84 -4.24 % $ 27.9 M israelIsrael
Viela Bio, Inc. Viela Bio, Inc.
VIE
- - $ 2.91 B usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
$ 13.98 1.27 % $ 5.7 B irlandaIrlanda
AbbVie AbbVie
ABBV
$ 233.57 0.64 % $ 413 B usaUSA
Blueprint Medicines Corporation Blueprint Medicines Corporation
BPMC
- - $ 8.14 B usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
AIM ImmunoTech AIM ImmunoTech
AIM
$ 0.8 -11.6 % $ 38.5 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.83 5.37 % $ 4.53 M chinaChina
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
$ 20.67 -1.38 % $ 2.61 B usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Cleveland BioLabs, Inc. Cleveland BioLabs, Inc.
CBLI
- -7.31 % $ 49 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA